Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• "Moderate Buy" consensus from six analysts (four buys, one hold, one sell) with an average 1‑year price target of $14.25.
• Orchestra BioMed posted a surprise quarterly beat — EPS $0.26 vs. estimate -$0.38 and revenue $30.92M vs. $0.93M expected — though the firm still shows negative ROE and net margin and analysts expect -1.68 EPS for the year.
• Insider David P. Hochman bought 10,000 shares at $4.29 (bringing his holding to ~1.09M shares); insiders own 8.10% of the stock while institutional investors hold about 53.2%.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has received an average rating of "Moderate Buy" from the six analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $14.25.

OBIO has been the subject of a number of recent analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. Wall Street Zen raised shares of Orchestra BioMed from a "strong sell" rating to a "hold" rating in a research note on Saturday, March 14th. Barclays lifted their price target on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an "overweight" rating in a research note on Friday, January 9th. Finally, Weiss Ratings cut shares of Orchestra BioMed from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, April 21st.

Insider Activity at Orchestra BioMed

In other news, insider David P. Hochman purchased 10,000 shares of the company's stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $4.29 per share, with a total value of $42,900.00. Following the purchase, the insider owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.10% of the company's stock.

Institutional Investors Weigh In On Orchestra BioMed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Simplify Asset Management Inc. bought a new stake in Orchestra BioMed during the 1st quarter valued at about $932,000. Cannon Global Investment Management LLC bought a new stake in Orchestra BioMed during the 1st quarter valued at about $96,000. Virtu Financial LLC bought a new stake in Orchestra BioMed during the 4th quarter valued at about $57,000. XTX Topco Ltd lifted its holdings in Orchestra BioMed by 44.6% during the 4th quarter. XTX Topco Ltd now owns 50,358 shares of the company's stock valued at $209,000 after buying an additional 15,540 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Orchestra BioMed during the 4th quarter valued at about $76,000. Institutional investors own 53.20% of the company's stock.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $3.93 on Friday. The stock's fifty day moving average is $4.34 and its 200 day moving average is $4.26. Orchestra BioMed has a fifty-two week low of $2.20 and a fifty-two week high of $5.42. The firm has a market capitalization of $235.33 million, a PE ratio of -3.48 and a beta of 0.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.43 and a current ratio of 6.45.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.64. The company had revenue of $30.92 million for the quarter, compared to analyst estimates of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%. On average, sell-side analysts anticipate that Orchestra BioMed will post -1.68 earnings per share for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.